Polyrizon shares surge 118.76% intraday after reporting preclinical data showing longer adhesion time for naloxone hydrogel and completing manufacturing scale-up for 2026 trials.

Polyrizon surged 118.76% intraday, driven by the release of preclinical data showing its proprietary naloxone hydrogel demonstrated significantly longer adherence time compared to commercial products (p<0.0001) and the successful completion of a manufacturing scale-up milestone for its PL-14 nasal spray platform, enabling large-scale production for 2026 clinical trials. The company announced on December 3 that its naloxone hydrogel showed statistically significant (p<0.0001) extended adherence on an ex vivo rabbit nasal mucosa model compared to existing naloxone sprays, supporting potential for prolonged nasal deposition. On December 2, it also announced completing the PL-14 nasal spray platform's manufacturing scale-up, transitioning from lab-scale to large-scale production while validating formula quality stability, ensuring compliance with U.S. and European standards for 2026 clinical trials.